Donepezil Zydus (Donepezil Hydrochloride)

Donepezil Zydus is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease. It may be prescribed as part of a comprehensive care plan that includes non‑pharmacologic interventions.

• Improves cognitive function such as memory and attention.
• Supports activities of daily living in patients with early‑stage Alzheimer’s disease.
• May be used in conjunction with other Alzheimer’s therapies under physician supervision.
• Intended for oral administration as directed by a healthcare professional.
• Typically prescribed after a confirmed diagnosis of Alzheimer’s disease.

Side effects of Donepezil Zydus vary in frequency and severity. Patients should be informed about both common and potentially serious reactions.

Common

• Nausea or vomiting
• Diarrhea
• Insomnia or abnormal dreams
• Muscle cramps or weakness
• Loss of appetite
• Fatigue

Serious

• Severe bradycardia or heart block
• Syncope (fainting)
• Gastrointestinal bleeding
• Persistent vomiting leading to dehydration
• Allergic reactions such as rash, pruritus, or angioedema

Before starting Donepezil Zydus, certain precautions should be considered to ensure safe use.

• Assess cardiac history, especially bradyarrhythmias or recent myocardial infarction.
• Evaluate liver function, as hepatic impairment may affect drug metabolism.
• Monitor for signs of gastrointestinal bleeding, particularly in patients on NSAIDs or anticoagulants.
• Use caution in patients with a history of seizures.
• Discuss pregnancy and lactation status with a healthcare provider, as safety data are limited.
• Review all concomitant medications to avoid potential interactions.

Donepezil Zydus can interact with several drug classes. Understanding these interactions helps minimize adverse effects.

Avoid

• Strong anticholinergic agents (e.g., diphenhydramine, atropine) which may counteract therapeutic effects.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and anticoagulants that increase bleeding risk.
• Certain antiarrhythmic drugs (e.g., quinidine) that may exacerbate cardiac conduction issues.

Use with caution

• Other cholinesterase inhibitors or memantine when combined therapy is considered.
• Beta‑blockers or calcium channel blockers that affect heart rate.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) which may increase donepezil plasma levels.